PT970095E
(pt)
*
|
1997-03-07 |
2004-03-31 |
Metabasis Therapeutics Inc |
Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
|
AU6452098A
(en)
|
1997-03-07 |
1998-09-22 |
Metabasis Therapeutics, Inc. |
Novel purine inhibitors of fructose-1,6-bisphosphatase
|
US6312662B1
(en)
*
|
1998-03-06 |
2001-11-06 |
Metabasis Therapeutics, Inc. |
Prodrugs phosphorus-containing compounds
|
AU767599B2
(en)
|
1998-03-06 |
2003-11-20 |
Metabasis Therapeutics, Inc. |
Novel prodrugs for phosphorus-containing compounds
|
CA2343027A1
(en)
|
1998-09-09 |
2000-03-16 |
Metabasis Therapeutics, Inc. |
Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
|
ID28787A
(id)
|
1998-11-03 |
2001-07-05 |
Basf Ag |
2-fenilbenzimidazol tersubstitusi, pembuatannya dan penggunaannya
|
ATE300288T1
(de)
*
|
1998-12-24 |
2005-08-15 |
Metabasis Therapeutics Inc |
Zusammensetzung enthaltend insulin- sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
|
US6756360B1
(en)
*
|
1998-12-24 |
2004-06-29 |
Metabasis Therapeutics, Inc. |
Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
|
US7205404B1
(en)
|
1999-03-05 |
2007-04-17 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing prodrugs
|
EP1724276A1
(de)
|
1999-03-05 |
2006-11-22 |
Metabasis Therapeutics, Inc. |
Neue Phosphor enthaltende Medikamentenvorläuferverbindungen
|
US6831069B2
(en)
|
1999-08-27 |
2004-12-14 |
Ribapharm Inc. |
Pyrrolo[2,3-d]pyrimidine nucleoside analogs
|
EP1210354A1
(de)
|
1999-09-08 |
2002-06-05 |
Metabasis Therapeutics, Inc. |
Prodrugs für leberspezifische verabreichung von arzneimitteln
|
US6965033B2
(en)
*
|
1999-12-22 |
2005-11-15 |
Metabasis Therapeutics, Inc. |
Bisamidate phosphonate prodrugs
|
AU2006202624B2
(en)
*
|
1999-12-22 |
2008-08-14 |
Metabasis Therapeutics, Inc. |
Novel bisamidate phosphonate prodrugs
|
ATE385421T1
(de)
|
2000-01-21 |
2008-02-15 |
Novartis Pharma Gmbh |
Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
|
RU2002126616A
(ru)
*
|
2000-03-08 |
2004-03-20 |
Метабэйсис Терапьютикс, Инк. (Us) |
Новые арильные ингибиторы фруктозо-1, 6-бисфосфатазы
|
US7563774B2
(en)
*
|
2000-06-29 |
2009-07-21 |
Metabasis Therapeutics, Inc. |
Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
|
CZ20035A3
(cs)
*
|
2000-07-06 |
2003-05-14 |
Metabasis Therapeutics, Inc. |
Kombinace FBPázových inhibitorů a antidiabetických činidel užitečná při léčení diabetes
|
JP4332496B2
(ja)
*
|
2002-05-13 |
2009-09-16 |
メタバシス・セラピューティクス・インコーポレイテッド |
Pmeaおよびpmpa環生成合成
|
CA2485702C
(en)
*
|
2002-05-13 |
2011-07-19 |
Metabasis Therapeutics, Inc. |
Novel phosphonic acid based prodrugs of pmea and its analogues
|
KR101115210B1
(ko)
*
|
2002-10-31 |
2012-04-12 |
메타베이시스 테라퓨틱스, 인크. |
신규 시타라빈 모노포스페이트 전구약물
|
RU2422450C2
(ru)
|
2003-11-19 |
2011-06-27 |
Метабазис Терапеутикс, Инк. |
Новые фосфорсодержащие тиромиметики
|
US7129049B2
(en)
*
|
2003-12-22 |
2006-10-31 |
Regents Of The University Of Minnesota |
Method of detecting equine glycogen storage disease IV
|
AU2005254940A1
(en)
*
|
2004-06-08 |
2005-12-29 |
Metabasis Therapeutics, Inc. |
Lewis acid mediated synthesis of cyclic esters
|
WO2006023515A2
(en)
*
|
2004-08-18 |
2006-03-02 |
Metabasis Therapeutics, Inc. |
Novel thiazole inhibitors of fructose 1,6-bisphosphatase
|
TWI375673B
(en)
|
2005-04-11 |
2012-11-01 |
Abbott Lab |
1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
|
US7728026B2
(en)
|
2005-04-11 |
2010-06-01 |
Abbott Laboratories, Inc. |
2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
|
TW200720255A
(en)
|
2005-07-13 |
2007-06-01 |
Taiho Pharmaceutical Co Ltd |
Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
|
EP1752450A1
(de)
|
2005-08-01 |
2007-02-14 |
Merck Sante |
Imidazolderivate als Fruktose-1,6-biphosphataseinhibitoren und pharmazeutische Zusammensetzungen diese enthaltend
|
CN102908350B
(zh)
|
2005-09-14 |
2014-07-23 |
武田药品工业株式会社 |
用于治疗糖尿病的二肽基肽酶抑制剂
|
ES2342007T3
(es)
|
2005-11-15 |
2010-06-30 |
Abbott Laboratories |
1h-benzimidazol-4-carboxamidas sustituidos eficaces como inhibidores de (parp).
|
MX2008014004A
(es)
|
2006-05-02 |
2008-11-12 |
Abbott Lab |
1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
|
US8466096B2
(en)
*
|
2007-04-26 |
2013-06-18 |
Afton Chemical Corporation |
1,3,2-dioxaphosphorinane, 2-sulfide derivatives for use as anti-wear additives in lubricant compositions
|
US8067613B2
(en)
|
2007-07-16 |
2011-11-29 |
Abbott Laboratories |
Benzimidazole poly(ADP ribose)polymerase inhibitors
|
EP2058308A1
(de)
|
2007-11-12 |
2009-05-13 |
Merck Sante |
Benzimidazoldihydrothiadiazinonderivate als Fructose-1,6-biphosphatase-Hemmer und diese enthaltende pharmazeutische Zusammensetzungen.
|
PL2294066T3
(pl)
|
2008-04-28 |
2015-02-27 |
Janssen Pharmaceutica Nv |
Benzimidazole jako inhibitory hydroksylazy prolilowej
|
MX2011003239A
(es)
|
2008-09-26 |
2011-04-28 |
Merck Sharp & Dohme |
Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.
|
WO2010047982A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
JP5557845B2
(ja)
*
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
US8759539B2
(en)
|
2008-11-17 |
2014-06-24 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
WO2010083199A1
(en)
|
2009-01-19 |
2010-07-22 |
Abbott Laboratories |
Benzthiazole inhibitors of poly(adp-ribose)polymerase
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
EP2805951B1
(de)
|
2009-03-20 |
2018-03-14 |
Metabasis Therapeutics, Inc. |
Inhibitoren von Diacylglycerin-O-acyltransferase 1 (DGAT-1) und Verwendungen davon
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011508A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
EP2464228B1
(de)
|
2009-08-13 |
2017-12-06 |
Merck Sharp & Dohme Corp. |
Substituierte cyclopropylverbindungen, zusammensetzungen mit solchen verbindungen und behandlungsverfahren damit
|
EP2473047B1
(de)
|
2009-09-02 |
2014-08-13 |
Merck Sharp & Dohme Corp. |
Aminotetrahydropyrane als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
PT2531501E
(pt)
|
2010-02-03 |
2014-02-17 |
Takeda Pharmaceutical |
Inibidores da cinase de regulação do sinal de apoptose 1
|
EP2538783B1
(de)
|
2010-02-22 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Substituierte aminotetrahydrothiopyrane als dipeptidylpeptidase-iv-hemmer zur behandlung von diabetes
|
EP2538784B1
(de)
|
2010-02-25 |
2015-09-09 |
Merck Sharp & Dohme Corp. |
Benzimidazolderivate als antidiabetika
|
WO2011146358A1
(en)
|
2010-05-21 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
US8742110B2
(en)
|
2010-08-18 |
2014-06-03 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
KR101594002B1
(ko)
|
2010-10-06 |
2016-02-15 |
글락소스미스클라인 엘엘씨 |
Pi3 키나제 억제제로서의 벤즈이미다졸 유도체
|
EP2677869B1
(de)
|
2011-02-25 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Neue cyclische azabenzimidazolderivate als antidiabetika
|
US8957062B2
(en)
|
2011-04-08 |
2015-02-17 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
EP2714678A1
(de)
|
2011-06-02 |
2014-04-09 |
Intervet International B.V. |
Imidazolderivate
|
US9006228B2
(en)
|
2011-06-16 |
2015-04-14 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
US9422266B2
(en)
|
2011-09-30 |
2016-08-23 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
EP2771000B1
(de)
|
2011-10-24 |
2016-05-04 |
Merck Sharp & Dohme Corp. |
Substituierte piperidinylverbindungen als gpr119-agonisten
|
AU2012328763A1
(en)
|
2011-10-25 |
2014-05-01 |
Janssen Pharmaceutica Nv |
Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo(d)imidazol-2-yl)-1H-pyrazole-4-carboxylic acid
|
WO2013068328A1
(en)
|
2011-11-07 |
2013-05-16 |
Intervet International B.V. |
Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
|
WO2013068439A1
(en)
|
2011-11-09 |
2013-05-16 |
Intervet International B.V. |
4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
|
CA2855009C
(en)
|
2011-11-15 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
EP2814485A4
(de)
|
2012-02-17 |
2015-08-26 |
Merck Sharp & Dohme |
Dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
|
EP2838906A4
(de)
|
2012-04-16 |
2015-07-15 |
Kaneq Pharma Inc |
Fusionierte aromatische phosphonatderivate als vorläufer für ptp-1b-inhibitoren
|
EP2874622A4
(de)
|
2012-07-23 |
2015-12-30 |
Merck Sharp & Dohme |
Behandlung von diabetes mit dipeptidylpeptidase-iv-hemmern
|
RU2015106909A
(ru)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
Антидиабетические трициклические соединения
|
EP2888008B1
(de)
|
2012-08-22 |
2018-12-26 |
Merck Sharp & Dohme Corp. |
Neuartige azabenzimidazol-tetrahydrofuranderivate
|
WO2014031441A1
(en)
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel benzimidazole tetrahydrofuran derivatives
|
EP2888005B1
(de)
|
2012-08-22 |
2019-04-03 |
Merck Sharp & Dohme Corp. |
Neuartige azabenzimidazol-hexahydrofuro[3,2-b]furan-derivate
|
EP2887807B1
(de)
|
2012-08-22 |
2019-09-18 |
Merck Sharp & Dohme Corp. |
Benzimidazol-hexahydrofuro[3,2-b]furanderivate als amp-aktivierte proteinkinase-aktivatoren
|
US9527839B2
(en)
|
2012-08-22 |
2016-12-27 |
Merck Sharp & Dohme Corp. |
Benzimidazole tetrahydropyran derivatives
|
EP2888006B1
(de)
|
2012-08-22 |
2019-04-24 |
Merck Sharp & Dohme Corp. |
Neuartige azabenzimidazol-tetrahydropyran-derivate als ampk aktivatoren
|
US9453038B2
(en)
|
2012-12-17 |
2016-09-27 |
Merck Sharp & Dohme Corp. |
Glucokinase activator compounds, compositions containing such compounds, and methods of treatment
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EP3068768B1
(de)
|
2013-11-15 |
2019-07-31 |
Merck Sharp & Dohme Corp. |
Antidiabetische tricyclische verbindungen
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
EP3097101B1
(de)
|
2014-01-24 |
2020-12-23 |
Merck Sharp & Dohme Corp. |
Isochinolinderivate als mgat2-inhibitoren
|
CN106061984A
(zh)
|
2014-02-13 |
2016-10-26 |
配体药物公司 |
前药化合物及其用途
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EP3164136A4
(de)
|
2014-07-02 |
2018-04-04 |
Ligand Pharmaceuticals, Inc. |
Prodrug-verbindungen und verwendungen davon
|
WO2016022742A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2016022446A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
JP6581656B2
(ja)
|
2014-10-24 |
2019-09-25 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
グルカゴンおよびglp−1受容体のコアゴニスト
|
TN2017000113A1
(en)
|
2014-10-31 |
2018-07-04 |
Ngm Biopharmaceuticals Inc |
Compositions and methods of use for treating metabolic disorders
|
TW201625635A
(zh)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
|
EP3078378B1
(de)
|
2015-04-08 |
2020-06-24 |
Vaiomer |
Verwendung von faktor-xa-inhibitoren zur regulierung von glykämie
|
US10245264B2
(en)
|
2015-05-27 |
2019-04-02 |
Merck Sharp & Dohme Corp. |
Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
|
EP3310782B1
(de)
|
2015-05-28 |
2021-12-01 |
Merck Sharp & Dohme Corp. |
Als lösliche guanylat-cyclase-aktivatoren geeignete imidazopyrazinylderivate
|
US10800826B2
(en)
|
2015-10-05 |
2020-10-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
EP3383868B1
(de)
|
2015-11-30 |
2022-10-05 |
Merck Sharp & Dohme LLC |
Arylsulfonamide als blt1-antagonisten
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
WO2017197555A1
(en)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
EP3496715B1
(de)
|
2016-08-15 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Zur veränderung der konzentrationen von gallensäuren nützliche verbindungen zur behandlung von diabetes und kardiometabolischen erkrankungen
|
EP3496716B1
(de)
|
2016-08-15 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Verbindungen zur änderung der konzentrationen von gallensäuren zur behandlung von diabetes und kardiometabolischen erkrankungen
|
EP3515891B1
(de)
|
2016-09-20 |
2023-03-08 |
Merck Sharp & Dohme LLC |
Substituierte 1-methyl-1,2,3,4-tetrahydroisochinolin-moleküle als allosterische pcsk9-bindemittel
|
BR112019009731A2
(pt)
|
2016-11-18 |
2019-08-13 |
Merck Sharp & Dohme |
composto, composição farmacêutica, uso de um composto, e, método de tratamento
|
WO2018107415A1
(en)
|
2016-12-15 |
2018-06-21 |
Merck Sharp & Dohme Corp. |
Hydroxy isoxazole compounds useful as gpr120 agonists
|
CA3087932A1
(en)
|
2018-01-09 |
2019-07-18 |
Ligand Pharmaceuticals, Inc. |
Acetal compounds and therapeutic uses thereof
|
JOP20190150A1
(ar)
|
2018-06-21 |
2019-12-21 |
Merck Sharp & Dohme |
مركبات مناهضة لـ pcsk9
|
US20220177465A1
(en)
|
2019-04-04 |
2022-06-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
TW202123960A
(zh)
|
2019-08-30 |
2021-07-01 |
美商默沙東藥廠 |
Pcsk9拮抗劑化合物
|
EP3842060A1
(de)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Geheftete lactam-co-agonisten der glucagon- und glp-1-rezeptoren
|
EP3842449A1
(de)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Geklammerte olefin-co-agonisten der glucagon- und glp-1-rezeptoren
|
EP3842061A1
(de)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Geheftete triazol-co-agonisten der glucagon- und glp-1-rezeptoren
|
AR122092A1
(es)
|
2020-05-18 |
2022-08-10 |
Merck Sharp & Dohme |
Inhibidores de diacilglicerol o-aciltransferasa 2
|
CA3195014A1
(en)
|
2020-10-08 |
2022-04-14 |
Yeon-Hee Lim |
Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
|
EP4387645A1
(de)
|
2021-08-19 |
2024-06-26 |
Merck Sharp & Dohme LLC |
Verbindungen zur behandlung von erkrankungen im zusammenhang mit pcsk9-aktivität
|
US20230406885A1
(en)
|
2022-06-15 |
2023-12-21 |
Merck Sharp & Dohme Llc |
Cyclic peptides for trapping interleukin-1 beta
|
WO2024118858A1
(en)
|
2022-12-02 |
2024-06-06 |
Merck Sharp & Dohme Llc |
Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
|